Skip to main content
Funded Studies

Christine Bulawa, PhD

Senior Director, Research at FoldRx Pharmaceuticals, Inc

Location: Cambridge, MA United States

Christine Bulawa received a PhD in Biochemistry from the University of Wisconsin-Madison and was a postdoctoral fellow at the Massachusetts Institute of Technology. At Millenium Pharmaceuticals, Dr. Bulawa developed methods for target validation for the human pathogen Candida albicans that became a cornerstone of a partnership with Pfizer in the area of antifungal drug discovery. As part of this program, Dr. Bulawa’s research team developed genomic technologies such as mRNA arrays and successfully applied these to discover compound mechanism-of-action. In addition, Dr. Bulawa used yeast as a model system to advance targets and compounds in Millennium's Cardiovascular Biology, Metabolic Disease, Inflammation, and Oncology programs. At FoldRx Pharmaceuticals, Dr. Bulawa established a discovery program for Parkinson’s disease based on the misfolding, aggregation, and toxicity of the clinically relevant protein alpha-synuclein and developed novel assays applicable to protein trafficking diseases, such as Cystic Fibrosis, in which misfolded proteins fail to be transported to the correct cellular location.

Associated Grants

  • Elucidating the Mechanism of Action of J3, A Neuroprotective Small Molecule Candidate to Treat Parkinson's Disease


  • Determination and Validation of the Molecular Target of J3, a Neuroprotective Lead Compound, for Its Optimization as a Disease-modifying Candidate for Parkinson's Disease


  • Development of Inhibitors of Alpha-Synuclein Toxicity to Treat Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.